This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Epizyme Execs Pocket Cheap Stock Options, Tone Deaf to Shareholder Pain

With new stock option grants this week, Epizyme executives are sending an ugly message to aggrieved shareholders: We don't mind profiting from your pain.

Incyte Falls on Jakafi Solid-Tumor Setback

Incyte is halting all clinical trials intended to expand the use of its blood cancer drug Jakafi into solid tumors due to an insufficient level of efficacy.

Despite Many Drug Blowups, CTI Bio CEO Bianco Turns S--t Into Gold For Himself

In the latest blowup, excess patient deaths forced CTI Bio to yank a new drug application for the myelofibrosis drug pacritinib.

Northwest Bio Blames Short Sellers, Not Warning From Expert Doctor, for Stock Plunge

Frank comments and a warning from a doctor supervising pivotal brain cancer vaccine study for Northwest Bio are likely cause of sharp slide in stock price.

MannKind Fails Twitter Like It Does Afrezza

Someone needs to send MannKind executives a primer on the uses of Twitter hashtags.

Gilead: Most Valuable Biotech Asset in Market Is Our Own Stock

Foster City, Calif.-based biotech giant Gilead announced a new $12 billion share repurchase plan on Tuesday night in conjunction with fourth-quarter earnings.

Axovant Sinks on Pfizer Alzheimer's Drug Blowup

The disclosure that Pfizer shelved an Alzheimer's drug because of disappointing efficacy is driving down the market value of Axovant Sciences, which is developing a similar drug.

Exelixis Kidney Cancer Survival Benefit Doesn't Address Competitive Question

Exelixis didn't provide specifics about the duration of Cometriq's survival benefit, so it's not known if the new data will help the company compete any better against Bristol-Myers Squibb.

Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?

Biotech news and observations to start the week.

Merck Takes on Gilead With Sharply Lower Hepatitis C Drug Price

The list price for Merck's newly approved hepatitis C drug is lower than competing therapies from Gilead Sciences and Abbvie, which means a new price war could be heating up.

Page 1 of 351
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs